MedTrace Logo

Enbrel® in Psoriatic Arthritis

NCT00111124 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2013-05-15

No results posted yet for this study

Summary

This study is testing the effect of etanercept in treating both the skin and joint symptoms of psoriatic arthritis patients. Enbrel®, also known as etanercept, has already been approved by the Federal Food Drug Administration for the treatment of psoriatic arthritis. It is taken as an injection under the skin. Participants in the trial will be offered etanercept free of charge to be self-injected once weekly for 24 weeks. During that period they will have 5 appointments at the study center and will also be asked to complete assessments of their health.

Conditions

Interventions

DRUG

Enbrel®

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00111124 on ClinicalTrials.gov